U.S. markets closed

Inspire Medical Systems, Inc. (INSP)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
211.89-3.54 (-1.64%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
MACD

MACD

Previous Close215.43
Open217.02
Bid210.20 x 800
Ask221.79 x 800
Day's Range198.16 - 217.24
52 Week Range40.53 - 252.25
Volume427,530
Avg. Volume256,978
Market Cap5.748B
Beta (5Y Monthly)1.70
PE Ratio (TTM)N/A
EPS (TTM)-2.19
Earnings DateMay 03, 2021 - May 07, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est253.55
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Is Inspire Medical Systems (INSP) Stock a Buy For 2021?
    Insider Monkey

    Is Inspire Medical Systems (INSP) Stock a Buy For 2021?

    Wasatch Ultra Growth Fund recently released its Q4 2020 Investor Letter, a copy of which you can download here. The fund posted a return of 23.2% for the quarter, underperforming its benchmark, the Russell 2,000 Growth Index which returned 29.6% in the same quarter. You should check out Wasatch’s top 5 stock picks for investors […]

  • Inspire Medical Pops 6.4% As 2021 Revenue Outlook Outpaces Estimates
    SmarterAnalyst

    Inspire Medical Pops 6.4% As 2021 Revenue Outlook Outpaces Estimates

    Inspire Medical Systems' shares were up about 6.4% in Wednesday’s pre-market trading session after the medical technology company's 2021 revenue guidance topped the Street’s estimates. Meanwhile, it reported better-than-expected results for the fourth quarter. Inspire Medical (INSP) reported a 4Q loss of $0.28 per share, which was narrower than the year-ago period’s loss of $0.38 per share. Analysts were looking for a loss of $0.48 per share. Its revenues spiked 71% year-over-year to reach $46 million and handily exceeded analysts’ expectations of about $41.1 million. The top-line growth reflected “the continued impact of the restart from the COVID-19 pandemic with a high level of implant procedures and the opening of new implanting centers,” said the company’s CEO Tim Herbert. Inspire Medical activated 55 new medical centers in the U.S. during the quarter, exceeding its own guidance of opening 28 to 30 new centers. At the end of the quarter, the company had a total of 425 U.S. centers implanting Inspire therapy. As for 2021, Inspire Medical Systems expects to generate revenues in the range of $183-$188 million, versus the Street’s estimates of $171.7 million. Moreover, the 2021 revenue outlook reflects year-over-year growth of about 59% to 63%. (See Inspire Medical stock analysis on TipRanks) Further, the company expects to activate 34 to 38 new U.S. implanting centers in each quarter of 2021. Following the results, Oppenheimer analyst Suraj Kalia said, “INSP notes that it's back to pre-COVID levels, though we note that no other company in the sector has reported such a step-change, which makes the numbers all the more curious.” He maintained a Hold rating, citing “our continued concerns on DTC [direct-to-consumer] spend and patient selection/outcomes.” Overall, the Street has a cautiously optimistic outlook on the stock, with a Moderate Buy consensus rating based on 3 Buys and 3 Holds. The average analyst price target of $230.25 implies upside potential of about 4.4% to current levels. Shares have rallied by about 171.4% in one year. Related News:Square Drops 5.7% On 4Q Payment Volume MissEssential Properties’ 4Q AFFO Misses Estimates; Street Stays BullishPioneer Natural’s 4Q Profit Sinks 55%; Shares Slip More recent articles from Smarter Analyst: Arena Posts Worse-Than-Feared Quarterly Loss As Sales Disappoint Wells Fargo Inks Deal To Sell Asset Management Arm For $2.1B PubMatic’s 4Q Earnings Beat Estimates Post-IPO; Shares Spike 12% After-Hours Essential Properties’ 4Q AFFO Misses Estimates; Street Stays Bullish

  • Benzinga

    Recap: Inspire Medical Systems Q4 Earnings

    Shares of Inspire Medical Systems (NYSE:INSP) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 26.32% over the past year to ($0.28), which beat the estimate of ($0.48). Revenue of $46,009,000 up by 71.00% from the same period last year, which beat the estimate of $41,070,000. Outlook Inspire Medical Sees FY21 Sales $183M-$188M vs $171.7M Estimate Details Of The Call Date: Feb 23, 2021 Time: 05:00 PM View more earnings on INSP ET Webcast URL: http://public.viavid.com/player/index.php?id=143162 Technicals 52-week high: $239.40 Company's 52-week low was at $40.53 Price action over last quarter: Up 39.33% Company Overview Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and Europe wherein, it generates a majority of its revenue from the United States. See more from BenzingaClick here for options trades from BenzingaEarnings Scheduled For February 23, 2021© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.